A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Q1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balance at September 30, 2023Company to host conference call today at...
Ranked 118th Fastest Growing Company in North AmericaRanked 23rd Fastest Growing Life Sciences CompanyDENVER, CO / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics,...
DENVER, CO / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September...
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD...
During this fireside chat we welcome Aytu BioPharma CEO Josh Disbrow. Aytu is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. This Fireside Chat was recorded during the Lytham Partners Fall...
ENGLEWOOD, CO / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings...
Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millionRecord Q4 2023 total prescriptions increased 32% compared to Q4 2022Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023Company to host conference call today at...
ENGLEWOOD, CO / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the...
ENGLEWOOD, CO / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the...
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets for the treatment of ADHDENGLEWOOD, CO and GIVATAYIM, ISRAEL / July 31, 2023 / Aytu BioPharma, Inc. (the...